Michael Bordonaro Selected Research

Butyrates (Butyrate)

1/2021	Hypothesis: Sam68 and Pygo2 mediate cell type-specific effects of the modulation of CBP-Wnt and p300-Wnt activities in Colorectal Cancer Cells.
1/2020	Further analysis of p300 in mediating effects of Butyrate in Colorectal Cancer Cells.
1/2020	Hypothesis: Retinoblastoma protein inactivation mediates effects of histone deacetylase inhibitor-induced Wnt hyperactivation in colorectal cancer cells.
1/2017	p300 Knockout Promotes Butyrate Resistance.
1/2017	ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC.
5/2016	Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells.
1/2016	Vimentin, colon cancer progression and resistance to butyrate and other HDACis.
1/2016	Effects of propolis and gamma-cyclodextrin on intestinal neoplasia in normal weight and obese mice.
7/2015	CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
1/2015	Hypothesis: cell signalling influences age-related risk of colorectal cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Bordonaro Research Topics

Disease

23	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2004
14	Neoplasms (Cancer) 01/2021 - 01/2008
11	Colonic Neoplasms (Colon Cancer) 03/2019 - 01/2004
5	Carcinogenesis 04/2019 - 01/2013
3	Obesity 01/2021 - 01/2015
3	Carcinoma (Carcinomatosis) 01/2017 - 01/2002
3	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2013 - 01/2002
2	Adenoma (Adenomas) 01/2016 - 01/2014
1	Overweight 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Inflammation (Inflammations) 03/2019
1	Intestinal Neoplasms (Intestinal Cancer) 01/2018
1	Hyperthermia 05/2016
1	Sarcoma (Soft Tissue Sarcoma) 05/2016
1	Polyps 01/2016
1	Neoplasm Metastasis (Metastasis) 01/2016
1	Progeria (Hutchinson Gilford Syndrome) 01/2015
1	Hyperglycemia 01/2009
1	Type 2 Diabetes Mellitus (MODY) 01/2009
1	Insulin Resistance 01/2009

Drug/Important Bio-Agent (IBA)

23	Butyrates (Butyrate)IBA 01/2021 - 01/2002
12	Dietary Fiber FDA Link 01/2021 - 07/2004
9	beta CateninIBA 01/2021 - 01/2002
8	Histone Deacetylase InhibitorsIBA 01/2021 - 01/2011
6	Calcibiotic Root Canal SealerIBA 01/2015 - 01/2004
2	Volatile Fatty AcidsIBA 03/2019 - 01/2002
2	Propolis (Bee Bread)IBA 01/2018 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2015
2	gamma-cyclodextrinIBA 01/2018 - 01/2016
2	Transcription Factors (Transcription Factor)IBA 01/2017 - 01/2009
2	CateninsIBA 07/2015 - 01/2013
1	A-factor (Streptomyces)IBA 01/2021
1	AdipokinesIBA 01/2021
1	AntipyreticsIBA 01/2021
1	ICG 001IBA 01/2021
1	Retinoblastoma ProteinIBA 01/2020
1	Lithocholic AcidIBA 03/2019
1	Bile Acids and Salts (Bile Acids)IBA 03/2019
1	Deoxycholic Acid (Sodium Deoxycholate)IBA 03/2019
1	amlexanox (Aphthasol)FDA Link 01/2019
1	Nonsense Codon (Nonsense Mutation)IBA 01/2019
1	ProteomeIBA 01/2018
1	Food Additives (Food Additive)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 05/2016
1	VimentinIBA 01/2016
1	CREB-Binding ProteinIBA 07/2015
1	CytokinesIBA 01/2015
1	PolyphenolsIBA 01/2014
1	Pharmaceutical PreparationsIBA 01/2014
1	RNA (Ribonucleic Acid)IBA 01/2013
1	Recombinant DNA (Recombinant DNA Research)IBA 01/2013
1	LigandsIBA 06/2011
1	Insulin (Novolin)FDA Link 01/2009
1	SolutionsIBA 05/2008
1	Fatty Acids (Saturated Fatty Acids)IBA 07/2004
1	LithiumIBA 01/2004
1	Butyric Acid (Butanoic Acid)IBA 01/2002

Therapy/Procedure

7	Therapeutics 01/2020 - 07/2008